A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- Other: Sham
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Allegro Ophthalmics, LLC
- Target Recruit Count
- 42
- Registration Number
- NCT03626636
- Locations
- 🇺🇸
Medical Center Ophthalmology Associates, San Antonio, Texas, United States
🇺🇸Valley Retina Institute, McAllen, Texas, United States
🇺🇸Retina Vitreous Associates Medical Group, Beverly Hills, California, United States
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
- Conditions
- Non-Proliferative Diabetic Retinopathy
- Interventions
- Drug: 2.0mg Luminate®Drug: 3.0mg Luminate®Drug: 1.0mg Luminate®Other: Balanced Salt Solution for intravitreal injection in 0.10cc
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Allegro Ophthalmics, LLC
- Target Recruit Count
- 105
- Registration Number
- NCT02435862
- Locations
- 🇺🇸
New England Retina Associates, New London, Connecticut, United States
🇺🇸UCI Medical Center, Orange, California, United States
🇺🇸Illinois Retina Center, Springfield, Illinois, United States
Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Allegro Ophthalmics, LLC
- Target Recruit Count
- 218
- Registration Number
- NCT02348918
- Locations
- 🇺🇸
Retina Specialty Institute, Pensacola, Florida, United States
🇺🇸Orange County Retina Medical Group, Santa Ana, California, United States
🇺🇸Center for Retina and Macular Disease, Winter Haven, Florida, United States
A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion
- Conditions
- Symptomatic Focal Vitreomacular Adhesion
- Interventions
- Drug: 2.0mg of ALG-1001
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Allegro Ophthalmics, LLC
- Target Recruit Count
- 45
- Registration Number
- NCT02153476
- Locations
- 🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸California Retina Consultants, Santa Barbara, California, United States
🇺🇸Center for Retinal and Macular Disease, Winter Haven, Florida, United States
A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Allegro Ophthalmics, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT01749891
- Locations
- 🇲🇽
APEC Hospital La Ceguera, Mexico City, Mexico
Safety Study of ALG- 1001 to Treat Diabetic Macular Edema
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2012-12-07
- Lead Sponsor
- Allegro Ophthalmics, LLC
- Registration Number
- NCT01482871
- Locations
- 🇲🇽
Apec Hospital La Ceguera, Mexico City, Mexico